Data / Federal grants / RFA-DK-28-116
Multimodal AI to Accelerate Precision Medicine for Type 1 Diabetes (U01- Clinical Trials Not Allowed)
National Institutes of Health (Department of Health and Human Services) expects to post this opportunity around December 1, 2026, with applications due around February 10, 2027. It lists 1 award expected, $5 million in total.
SpecStream is the live web data engine for teams and agents. It reads every open and forecast federal opportunity on Grants.gov each morning, and this page is that reading. Describe your organization once and the grants that fit arrive in your sheet, CRM, Slack or agent as they are posted.
Key facts
- Opportunity number
- RFA-DK-28-116
- Status
- Forecast
- Posted
- August 20, 2026
- Closes
- February 10, 2027
- Expected awards
- 1
- Total funding
- $5,000,000
- Cost sharing
- Not required
- Funding instrument
- Cooperative Agreement
- Category
- Health
- Assistance listing
- 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research
- Contact
- Division of Diabetes, Endocrinology and Metabolic Diseases · [email protected] · [email protected]
Who can apply
- Public and State controlled institutions of higher education
- Public housing authorities/Indian housing authorities
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Native American tribal governments (Federally recognized)
- Private institutions of higher education
- City or township governments
- Special district governments
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
- State governments
- County governments
- For profit organizations other than small businesses
- Independent school districts
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;Non-domestic (non-U.S.) Entities (Foreign Institutions).
What the agency says
Type 1 diabetes (T1D) is a complex disease involving interactions among many different cell types, tissues, organs and biological processes. Genetics, the environment, and lifestyle all play a role in disease development and progression. Over the past two decades, the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) has supported major T1D research consortia covering basic, translational, and clinical research. Each consortium has focused on different aspects of T1D, such as specific organs, stages of disease or clinical outcomes. Together, these consortia have collected large longitudinal and multimodal datasets using standardized protocols and coordinated studies. While individual consortia have improved our understanding of specific areas, combining their work offers a rare opportunity to see how different biological processes interact to drive T1D development and progression. This integrated view can answer fundamental questions about T1D biology that cannot be answered using individual datasets or studies alone. Recent advances in artificial intelligence (AI) now make it possible to integrate these complementary datasets and study T1D across various tissues, disease stages, and biological levels. Building on these resources, NIDDK will support a coordinated, milestone-driven research project to answer fundamental questions about T1D biology and accelerate the development of personalized medicine. The project will combine multimodal human pancreas and clinical datasets to better understand how biological processes interact as T1D develops and progresses. The research will generate new insights into T1D biology, help us understand the different forms and stages of T1D, identify biomarkers, and inform new approaches for disease prevention, intervention, and treatment. To support the research, the project will develop and test advanced multimodal AI models. It will also develop AI-enabled research workflows, new methods to integrate data, and privacy-preserving synthetic datasets.
Other open grants from the Department of Health and Human Services
| Opportunity | Status | Closes | Award ceiling | Total funding | Record |
|---|---|---|---|---|---|
| Long-term health outcomes of people living with spina bifida CDC-RFA-DD-26-0222 | Open | Oct 26 | $300,000 | $3,000,000 | grants.gov |
| GREGoRi Data Coordination and Outreach Center (U01, Clinical Trials Not Allowed) RFA-HG-27-011 | Open | Oct 30 | $1,250,000 | $2,000,000 | grants.gov |
| GREGoRi Innovation Projects (U01 Clinical Trial Optional) RFA-HG-27-013 | Open | Oct 30 | $500,000 | $7,500,000 | grants.gov |
| GREGoRi Technology Integration Center (U01, Clinical Trials Optional) RFA-HG-27-012 | Open | Oct 30 | $2,250,000 | $3,000,000 | grants.gov |
| HEAL Initiative: Whole Joint Health Program (R61/R33 Clinical Trial Required) PAR-27-045 | Open | Oct 30 | grants.gov | ||
| Clinical Observational (CO) Studies in Musculoskeletal, Rheumatic, and Skin Diseases (R01 Clinical Trial Not Allowed) PAR-24-280 | Open | Nov 2 | grants.gov |
All grants open to Public colleges and universities · All grants open to Public housing authorities/Indian housing authorities · All grants open to Nonprofits (501(c)(3)) · Everything closing in February 2027
Read from the Grants.gov API, last updated 2026-10-23. The agency's notice on Grants.gov is the official record; check it before you apply.